Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 38, Issue 12, 2011, Pages 2540-2547

  Stamp, Lisa K ^a   Barclay, Murray L ^a   O'Donnell, John L ^b   Zhang, Mei ^b   Drake, Jill ^c   Frampton, Christopher ^a   Chapman, Peter T ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Methotrexate polyglutamates; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE;

28 JOINT DISEASE ACTIVITY SCORE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; ERYTHROCYTE LEVEL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STEADY STATE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ERYTHROCYTES; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; METHOTREXATE; MIDDLE AGED; POLYGLUTAMIC ACID;

EID: 82755176607     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110481     Document Type: Article

References (31)

1. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multi-national evidence based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis 2009;68:1086-93.
2. Chungi V, Bourne D, Dittert L. Drug absorption VIII: Kinetics of GI absorption of methotrexate. J Pharm Sci 1978;67:560-1. (Pubitemid 8331327)
3. Hamilton R, Kremer J. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86-90.
4. Brooks P, Spruill W, Parish R, Birchmore D. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:91-4. (Pubitemid 20040135)
5. Jundt J, Browne B, Fiocco G, Steele A, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9. (Pubitemid 24031585)
6. Arthur A, Klinkhoff A, Teufel A. Safety of self-injection of gold and methotrexate. J Rheumatol 1999;26:302-5. (Pubitemid 29066732)
7. Osman A, Mulherin D. Is parenteral methotrexate worth trying? Ann Rheum Dis 2001;60:432.
8. Burbage G, Gupta R, Lim K. Intramuscular methotrexate in inflammatory rheumatic disease. Ann Rheum Dis 2001;60:1156. (Pubitemid 33096085)
9. Bingham S, Buch M, Lindsay S, Pollard A, White J, Emery P. Parenteral methotrexate should be given before biological therapy. Rheumatology 2003;42:1009-10. (Pubitemid 37220978)
10. Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004;63:1232-4. (Pubitemid 39273499)
11. Rozin A, Schapira D, Balbir-Gurman A, Braun-Moscovici Y, Markovits D, Militianu D, et al. Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann Rheum Dis 2002;61:756-7. (Pubitemid 34787722)
12. Braun J, Kastner P, Flaxenberg P, Wahrisch J, Hanke P, Demary W, et al. The clinical efficacy and safety of subcutaneous versus oral application of methotrexate in patients with active rheumatoid arthritis - results of a randomised, controlled, double-blind multicenter study [abstract]. Arthritis Rheum 2005;52 Suppl:S542.
13. Lambert C, Sandhu S, Lochead A, Hurst N, McRorie E, Dhillon V. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate. Arthritis Rheum 2004;50:364-71. (Pubitemid 38198819)
14. Tishler M, Caspi D, Graff E, Segal R, Peretz H, Yaron M. Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis. Br J Rheumatol 1989;28:422-3. (Pubitemid 19248531)
15. Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008;58:3299-308.
16. Stamp LK, O'Donnell JL, Chapman PT, Zhang M, James J, Frampton CM, et al. Determinants of red blood cell methotrexate polyglutamate concentrations in patients with rheumatoid arthritis on long-term MTX. Arthritis Rheum 2009;60:2248-56.
17. Becker M, van Haanhel L, Gaedigk R, Lasky A, Hoeltzel M, Stobaugh J, et al. Analysis of intracellular methotrexate polyglutamates in juvenile idiopathic arthritis: effect of route of administration upon intracellular methotrexate polyglutamate variability. Arthritis Rheum 2010;62:1803-12.
18. Stamp LK, O'Donnell JL, Chapman PT, Zhang M, James J, Frampton CMA, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients on longterm MTX therapy. Arthritis Rheum 2010;62:359-68.
19. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in rheumatoid arthritis patients treated with methotrexate: results of a multicentered cross sectional observational study. Ann Rheum Dis 2005;64:1180-5. (Pubitemid 41113353)
20. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74. (Pubitemid 39209513)
21. Angelis-Stoforidis P, Vajda FJE, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999;17:313-20. (Pubitemid 29265678)
22. Becker M, Gaedigk R, Van Haandel L, Thomas B, Lasky A, Hoeltzel M, et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum 2011;63:276-85.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
24. Prevoo M, van 't Hof M, Kuper H, van Leeuweii M, van de Putte L, van Riel P. Modified Disease Activity Scores that include twenty-eight joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)
26. Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit 2007;29:619-25. (Pubitemid 47494061)
27. Bharadwaj A, Agrawal S, Batley M, Hammond A. Use of parenteral methotrexate significantly reduces the need for biological therapy. Ann Rheum Dis 2008;47:222. (Pubitemid 351168237)
28. Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology 2010;49:2337-45.
29. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosyl-aminoimidazole-carboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985;82:4881-5. (Pubitemid 15249910)
30. Braun J, Kastner P, Flaxenberg P, Wahrisch J, Hanke P, Demary W, et al. Comparison of clinical efficacy and safety of subcutaneous versus oral methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2008;58:73-81.
31. Collins K, Aspey H, Todd A, Saravanan V, Rynne M, Kelly C. Methotrexate pneumonitis precipitated by switching from oral to parenteral administration. Ann Rheum Dis 2008;47:109-10. (Pubitemid 350286278)